Drug–target residence time and its implications for lead optimizationRobert A. Copeland(GlaxoSmithKline (United States)), David L. Pompliano(South College), Thomas D. Meek(GlaxoSmithKline (United States))Nature Reviews Drug DiscoveryAugust 4, 200610.1038/nrd2082Cited by 1,440SaveCiteExport RISWatch citationsAbstractRelated PapersCatalysis in chemistry and enzymologyWilliam P. Jencks|Medical Entomology and Zoology|1969|3.2kEvaluation of enzyme inhibitors in drug discovery. A guide for medicinal chemists and pharmacologists.Robert A. Copeland|PubMed|2005|1.1kStructure and mechanismNorman J. Oppenheimer, Thomas Leroy James|Academic Press eBooks|1989|822Steroid-hormone rapid actions, membrane receptors and a conformational ensemble modelAnthony W. Norman, Mathew T. Mizwicki, Derek P. G. Norman|Nature Reviews Drug Discovery|2004|566The kinetics of competitive radioligand binding predicted by the law of mass action.Harvey Motulsky, L C Mahan|Molecular Pharmacology|1984|418